Zelira Therapeutics Ltd. announced that it has received the final clinical report for its Phase 1a/2b medicinal cannabis trial for insomnia. The trial was undertaken at the world-class University of Western Australia (UWA) Centre for Sleep Science and was led by principal investigator Professor Peter Eastwood. The trial used a randomised, double-blind, cross-over design to assess the efficacy of Zelira's proprietary cannabis formulation (ZTL-101) to treat patients diagnosed with chronic insomnia symptoms. Twenty-three patients were treated for 14 nights with ZTL-101 and 14 nights with placebo, separated by a one-week washout period. After dosing commenced, each participant was able to take a single (0.5ml of 11.5mg total cannabinoids) or double (1 ml of 23mg total cannabinoids) their dose of the medication, delivered sublingually, according to their symptoms. Primary Endpoints Achieved: ZTL-101 is safe: No serious adverse events reported; Non-serious adverse events were mild and transient, with over 95% resolved by the next morning; Maximal dose was well tolerated. ZTL-101 is efficacious: Across all participants ISI scores decreased by 26% while those on the highest dose achieved a 36% reduction in symptoms as measured by the Insomnia Severity Index (ISI); ZTL-101 treatment was dose responsive; Patients on highest dose reclassified from `moderate' to `sub-clinical' insomnia according to ISI classification; Statistically significant reduction in ISI scores achieved at all doses vs placebo. Secondary Endpoints Achieved: ZTL-101 improved Objective and Subjective Measures of Insomnia (Tables 1-2); Statistically significant and dose responsive: Improvement in time spent asleep (33-65 min); Reduction in wake time during the night (10 min); Improvement in sleep quality; Improvement in feeling rested on waking; ZTL-101 improved Quality of Life; Statistically significant: Independent reduction in stress levels and fatigue; Improvement in functioning.